Stenocare A/S

STENO

DK0061078425

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:53 2024-04-19 am EDT			5-day change	1st Jan Change
5.22 ^DKK	+14.98%		-4.04%	+105.51%

Apr. 18	Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark	CI
Mar. 12	Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients	CI

STENOCARE comments on today's legalization of medical cannabis in Denmark

December 02, 2021 at 11:42 am EST

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

Legalisation of medical cannabis in Denmark has been passed by the Danish Parliament. The Pilot programme is extended with four years to allow all Danish doctors to prescribe medical cannabis for their patients and Danish cultivation and production of medical cannabis is now permanently legal.

Denmark has been among the first European countries to allow treatment with medical cannabis. This has been possible since January 2018 via the Danish Pilot Programme, that was initially planned for four years and ending by the end of this month. Today, the Parliament voted for a four year's extension of treatment with medical cannabis and for making Danish production permanently legal ("L44-A" and "L44-B").

This is positive news for both Danish patients and the medical cannabis industry. Subject to availability of regulatory approved products, patients are now able to continue their treatment and new patients can be allowed to be offered this treatment for the next four years. With the approval of the law, STENOCARE and the wider Danish medical cannabis industry also has clarity for their future.

Specifically, the extension of the Pilot Programme is a significant milestone to STENOCARE as it takes away a fundamental risk and paves the way for introduction of STENOCARE's new imported products to Danish patients as soon as approval from the Danish Medical Agency is in place. The new permanent legalization of cultivation is also very good timing in relation to STENOCARE's recent completion of its world-class indoor cultivation facility as it removes an all-important barrier to the planned European expansion.

Thomas Skovlund Schnegelsberg, CEO of STENOCARE is commenting:

"Today's news is an important milestone for Danish patients, for the Danish medical cannabis industry and for STENOCARE. With today's news, Denmark and STENOCARE is on track to become a leading producer of medical cannabis for patients in Europa and to become an important part of the hyper-growth expected within medical cannabis sector in the coming years".

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

STENOCARE's Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.

www.stenocare.com www.stenocare.dk www.stenocare.se

https://news.cision.com/stenocare/r/stenocare-comments-on-today-s-legalization-of-medical-cannabis-in-denmark,c3465298

https://mb.cision.com/Main/17551/3465298/1505061.pdf

Latest news about Stenocare A/S

Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark	Apr. 18	CI
Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients	Mar. 12	CI
Stenocare Gets Nod for Sale of Medical Cannabis Oil Product in Denmark	Feb. 26	MT
STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in Denmark	Feb. 26	CI
Stenocare A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Stenocare A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Danish Medical Cannabis Group Stenocare Secures Refinancing Deal	Jan. 12	MT
Stenocare A/S Reaches Refinancing Agreement Covering All Existing Debt of DKK 8.2 Million	Jan. 12	CI
Stenocare Aims to Boost Sales in Australia via Quest Biotech Pharma Team up	Dec. 14	MT
Stenocare A/S Enters into A New Partnership Agreement with Quest Biotech Pharma	Dec. 14	CI
Stenocare A/S Expands Presence with New Medical Cannabis Oil Product	Nov. 23	CI
Stenocare A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Stenocare to Supply, Sell Medical Cannabis in Germany; Shares Surge	23-10-30	MT
Stenocare Ready to Ship Medical Cannabis to German Patients	23-10-30	CI
Stenocare A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Stenocare A/S Provides Sales Guidance for the Year 2023	23-08-17	CI
Stenocare A/S Provides Update on Their Strong Danish Product Pipeline	23-07-27	CI
Stenocare A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-20	CI
Stenocare Raises DKK10.7 Million from Oversubscribed Rights Offering; Falls 10%	23-06-12	MT
Denmark’s Stenocare Teams Up with International Partner for New Cannabis Oil Product	23-06-02	MT
Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis Product	23-06-02	CI
Stenocare A/S Launches IT-Platform for Online Clinics	23-05-30	CI
Denmark's Stenocare Wins Regulatory Nod to Enter German Market	23-05-25	MT
Stenocare A/S Expands into Germany with Local Partner, ADREX Pharma	23-05-25	CI
Stenocare A/S Auditor Raises 'Going Concern' Doubt	23-03-15	CI

Chart Stenocare A/S

Duration

Period

More charts

Company Profile

STENOCARE A/S is a Denmark-based company, which is engaged in the production of medical cannabis products to patients. The Company's business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The Company distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
STENOCARE A/S	+105.51%	11.77M
DONG-E-E-JIAO CO.,LTD.	+40.86%	6.16B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.30%	4.49B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.93%	3.17B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.58%	3.01B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.70%	2.57B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+37.23%	1.8B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-12.78%	1.62B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.02%	1.56B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine

Stenocare A/S

Equities

STENO

DK0061078425

Pharmaceuticals

STENOCARE comments on today's legalization of medical cannabis in Denmark

Latest news about Stenocare A/S

Chart Stenocare A/S

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine